Per Källblad, Ph.D.
Chief Executive Officer
Per Källblad co-founded Beactica in 2006 and is Chief Executive Officer. He has significant international experience in interdisciplinary pharmaceutical research and has worked in collaborations with Aventis, Rhone-Poulenc Rorer, Roche, Cancer Research UK, Peakdale Molecular, Biovitrum and Tibotec.
Per received his Ph.D. in Drug Design from Cambridge University, UK. He was a founding scientist at De Novo Pharmaceuticals Ltd (1999-2004), a Cambridge University spin-off that raised £17.5m in venture capital to bring a new drug discovery tool to market. At Medivir AB he worked with preclinical strategies for therapeutic targets on internal and external projects (2004-2006).
Helena Danielson, Prof.
Chief Scientific Officer
Helena Danielson co-founded Beactica in 2006 and is Chief Scientific Officer. She is a specialist in enzyme-based drug discovery and has adapted biosensor technology for detailed studies of enzyme-inhibitor interactions. She has profound experience of the commercial drug discovery process through more than 15 years of collaborative research with industrial partners.
At the Karolinska Institute she initiated a research project on HIV protease as a drug target for AIDS. In 1987 this work lead to a collaboration with Medivir AB that has been ongoing since. Her longstanding work with Biacore AB has resulted in the development of new biosensor products of wide use in the discovery industry. She is Professor of Biochemistry at Uppsala University since 2002.
Bo Öberg, Prof.
Professor Bo Öberg, CEO of Medivir HIV Franchise AB, cofounded Medivir AB in 1988 and has held a number of executive and board positions with the company including Chairman of the Board from 1992 to 1996. He is currently CEO of Medivir HIV Franchise AB. Prior to founding Medivir, Bo was Senior Director of Antiviral Therapy R&D at Astra from 1978 to 1988. He has held corporate board positions with a number of companies including Clean Chemical Sweden AB, BioAgri AB, Agrivir AB and Accuro Immunology AB.
Bo Öberg became an adjunct professor at the Department of Virology at the Karolinska Institute in 1984. He has served, and continues to serve, on a number of scientific advisory committees. In particular, he is Chair of the Advisory Board of the RAPID Centre and Member of the Advisory Board of the Centre for Infectious Medicine. Bo was Member of the Board of the Swedish Research Council for Medicine, Director of the Board of the International Society for Antiviral Research and Member of the Committee on Biotechnology of the Swedish Board for Technical Development, Member of WHO Advisory Group on Antiviral Chemotherapy and a Member of the Royal Society of Sciences in Uppsala.
Gisela Sitbon, Ph.D.
Dr Gisela Sitbon, Deputy Region Director at Innovationsbron AB, has more than 25 years of life-science industry experience within the areas of strategic planning, business development, pharmaceutical R&D and quality assurance. She is a non-executive member of the board at a number of companies and organisations including Industrifonden, Innoventus AB, NorDiag ASA. Through her own company, ZENZ Bioscience Partner AB, Gisela provides consultancy in the areas of business focusing and business development to high-growth companies.
Gisela Sitbon worked for nearly ten years at Professional Genetics Laboratory AB in a number of senior rôles including Managing Director, Vice President Business Development and Head of Research & Development. Prior, she spent five years in several rôles including Section Head and Project Director at Karo Bio AB, a Swedish drug discovery and development company specializing in targeting nuclear receptors. Gisela gained her Doctorate of Medical Sciences from the Karolinska Institute in 1987.
